8-K: SKYX Platforms Director Passes Away, Nasdaq Compliance at Risk

SKYX Platforms Corp. announced the passing of a Board Director, leading to non-compliance with Nasdaq's independent director and audit committee composition rules, with a cure period granted.

Summary

• SKYX Platforms Corp. reported the passing of Efrat L. Greenstein Brayer, an independent director, on September 26, 2026.
• Ms. Greenstein Brayer was a member of the audit, compensation, and nominating/corporate governance committees.
• The company notified Nasdaq on September 28, 2026, that it is no longer in compliance with Nasdaq Listing Rule 5605(b)(1) (majority independent directors) and 5605(c)(2)(A) (audit committee composition).
• Nasdaq has granted a cure period, expiring on the earlier of the next annual meeting or September 26, 2027, to regain compliance.
• The company intends to take actions to regain compliance within the cure period, but success is not assured.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the unexpected passing of a key director and the subsequent non-compliance with Nasdaq listing rules, although a cure period is provided.

Positives

• Nasdaq has provided a cure period, allowing the company time to rectify the governance issues.
• The company intends to take sufficient actions to regain compliance.

Negatives

• The unexpected passing of an independent director has led to immediate non-compliance with Nasdaq's listing rules.
• The company is currently not in compliance with Nasdaq's requirements for a majority of independent directors and a minimum of three members on the audit committee.
• There is no assurance that the company will be able to regain compliance within the specified cure period.

Risks

• Failure to regain compliance with Nasdaq listing rules within the cure period could lead to delisting.
• The loss of a director with committee chair experience may impact governance and oversight functions.
• Uncertainty regarding the ability to regain compliance could negatively impact investor confidence.

Future Outlook

The company intends to take sufficient actions to regain compliance with Nasdaq governance requirements within the provided cure periods, but there can be no assurance of success.

Management Comments

• The Board and management are deeply saddened by her passing.
• The Company intends to take sufficient actions to regain compliance with the foregoing Nasdaq governance requirements on or before the expiration of the applicable cure periods provided in the Nasdaq Listing Rules.

Industry Context

StockSavvy.ai notes that maintaining compliance with exchange listing rules, particularly regarding board independence and audit committee composition, is critical for investor confidence and market access. Failure to do so can signal governance weaknesses.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased volatility and concern over Nasdaq listing status and governance.
• Creditors: May view the governance issue as a sign of instability, potentially impacting credit risk perception.
• Employees: May experience uncertainty regarding the company's future stability and market position.

Next Steps

• Take sufficient actions to regain compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A).
• Evidence compliance with Nasdaq rules by the earlier of the next annual meeting of stockholders or September 26, 2027 (or March 25, 2027, if the annual meeting is held before that date).

Key Dates

Recommendation

The passing of a director and subsequent Nasdaq non-compliance introduces significant uncertainty and risk. While a cure period is provided, the assurance of regaining compliance is not guaranteed. This warrants a cautious 'hold' stance until the governance issues are resolved and the company demonstrates a clear path back to full compliance.

Keywords

Board of Directors, Nasdaq Compliance, Audit Committee, Corporate Governance, Independent Director, Delisting Risk